BFH772 (VEGFR2 inhibitor): Practical Lab Guide

BFH772, also identified as CAS 890128-81-1 and supplied as SKU B6199, is a small-molecule VEGFR2 inhibitor intended for research workflows that require targeted modulation of VEGFR2-associated angiogenesis. No directly matched paper evidence is available for a specific protocol using this product, so the practical recommendations below distinguish product-dossier specifications from routine assay-design guidance.

What This Product Solves

Many angiogenesis experiments need a defined perturbation of VEGFR2 rather than a broadly acting cytotoxic or multikinase reagent. BFH772 addresses that need by providing a dossier-reported VEGFR2 kinase IC50 of 3 nM. This value is a potency reference for the reported assay context; it is not a universal cellular dose or a guaranteed concentration for every model.

The compound is chemically defined as 6-((6-(hydroxymethyl)pyrimidin-4-yl)oxy)-N-(3-(trifluoromethyl)phenyl)-1-naphthamide, with a molecular weight of 439.39 g/mol and formula C23H16F3N3O3. The dossier describes reduced potency against listed related receptors and lower activity against kinases including B-RAF, RET, and TIE-2. This profile makes BFH772 relevant as a VEGFR2 signaling pathway inhibitor, an angiogenesis inhibitor, and a tumor angiogenesis research compound, provided that selectivity is verified in the investigator’s own assay system.

For identity, lot documentation, purity information, and handling details, consult the BFH772 (VEGFR2 inhibitor) product page from APExBIO. The dossier reports purity above 96%, solubility in DMSO and ethanol, and insolubility in water. Those properties are central to experimental design: the compound is more appropriate for organic-stock workflows than for direct addition to aqueous buffers.

Protocol Parameters

The following parameters separate reported product values from workflow recommendations. They should be treated as starting points for assay qualification, not as a substitute for a validated concentration-response study.

• Assay: VEGFR2 biochemical kinase assay
  Value: IC50 3 nM
  Applicability: Potency reference for target-level assay planning
  Rationale: Use the reported value to define a concentration-response range, while recognizing that enzyme format, ATP concentration, substrate, incubation time, and readout can shift apparent potency
  Evidence basis: Product dossier
• Assay: DMSO stock preparation
  Value: Solubility at or above 53.4 mg/mL
  Applicability: Preparation of concentrated organic stocks before dilution into assay medium
  Rationale: DMSO is the more practical stock solvent reported for this water-insoluble compound; confirm visual clarity after preparation and dilution
  Evidence basis: Product dossier
• Assay: Ethanol stock preparation
  Value: Solubility at or above 15.33 mg/mL
  Applicability: Alternative organic-solvent stock when ethanol is compatible with the assay
  Rationale: Ethanol can be used only when the final solvent level is tolerated by the biological system and matched across controls
  Evidence basis: Product dossier plus workflow recommendation
• Assay: Solid or neat-material storage
  Value: −20 °C
  Applicability: Routine storage of the supplied material
  Rationale: Maintain the recommended temperature and limit unnecessary exposure to ambient conditions; long-term storage of solutions is not recommended
  Evidence basis: Product dossier
• Assay: Cell-based or ex vivo inhibition study
  Value: Constant final vehicle concentration across all treatment and control wells
  Applicability: Any experiment using DMSO or ethanol to deliver BFH772
  Rationale: Vehicle variation can alter cell viability, morphology, barrier behavior, or angiogenic readouts independently of VEGFR2 inhibition
  Evidence basis: Workflow recommendation
• Assay: Solution calculation and dilution
  Value: Molecular weight 439.39 g/mol
  Applicability: Conversion between weighed mass, molar stock concentration, and final assay concentration
  Rationale: Use the dossier molecular weight in all preparation calculations and document the lot, solvent, stock concentration, and dilution sequence
  Evidence basis: Product dossier

Workflow Setup and QC Checklist

Stock preparation

1. Confirm the SKU, CAS number, lot identity, purity statement, certificate of analysis, and safety data sheet before weighing or dispensing.
2. Calculate the required mass using 439.39 g/mol, then dissolve BFH772 in a compatible organic solvent. Prepare a concentration that remains within the reported solubility range and is practical for serial dilution.
3. Mix until the solution is visually clear. If haze, crystals, or precipitate appear, do not assume that the nominal concentration is accurate. Re-dissolve under validated conditions or prepare a fresh stock.
4. For aqueous addition, introduce the organic stock gradually into a well-mixed assay medium. Inspect the final working solution because a clear stock can still precipitate after dilution into water-based media.
5. Use freshly prepared working solutions when possible. Because long-term solution storage is not recommended, avoid building experiments around aged or repeatedly thawed solutions.

Assay controls and readouts

Include untreated, vehicle, and stimulated controls when the model uses VEGF-dependent activation. A VEGFR2-linked biochemical or phosphorylation readout can support target-level interpretation, while migration, sprouting, or tube-formation measurements can assess the associated angiogenic phenotype. Pair phenotype measurements with a viability or general cell-health readout so that reduced growth is not incorrectly reported as a selective anti-angiogenic effect.

Use a concentration-response design rather than a single concentration. The dossier IC50 can guide range selection, but cellular permeability, protein binding, exposure time, receptor abundance, and solvent tolerance may produce a different apparent response. Confirm that the vehicle is constant and that the assay signal remains within its validated dynamic range.

For a related discussion of stock preparation and assay controls, see BFH772 (VEGFR2 inhibitor): Practical Lab Guide; it complements this article by emphasizing handling and interpretation boundaries. For additional guidance on choosing protocol parameters, see BFH772 (VEGFR2 inhibitor): Technical Guidance and Protocol Parameters; that article expands on assay setup without changing the product’s solubility limitations.

Run-level QC

Record plate map, cell or enzyme lot, stimulation timing, solvent identity, stock preparation date, treatment duration, and raw signal values. Examine vehicle-treated morphology and baseline signal before interpreting inhibition. If the experiment is intended to support a selectivity claim, add an orthogonal target assay or a genetic comparator rather than relying only on one downstream phenotype.

Common Failure Modes and Fixes

• Precipitation after aqueous dilution: The compound is insoluble in water, and the solvent fraction can fall below what is needed to maintain solubility during dilution. Prepare a sufficiently concentrated stock, add it slowly with mixing, and inspect the working solution immediately and during the exposure period.
• Variable apparent potency between runs: Differences in vehicle level, cell density, VEGF stimulation, incubation time, or endpoint timing can shift the response. Standardize these variables and include a full vehicle control on every run.
• Overinterpretation of the 3 nM IC50: A biochemical IC50 does not establish a cellular IC50, effective exposure, or phenotypic threshold. Fit an independent concentration-response curve in each relevant model and report the assay context.
• Confusing reduced angiogenesis with nonspecific toxicity: Inhibition of proliferation or survival can reduce sprouting and migration signals. Add viability, morphology, and, where appropriate, an orthogonal angiogenesis endpoint.
• Unsupported selectivity conclusions: The dossier-reported selectivity profile does not prove complete kinase exclusivity. Also verify receptor nomenclature in source assay records, since FLK-1 may be used as a VEGFR2 designation in some contexts. Use biochemical counterscreens or genetic controls before assigning a phenotype solely to VEGFR2.
• Loss of solution quality during storage: Aged or repeatedly handled solutions may have altered concentration or visible instability. Prepare fresh working material and retain the solid at −20 °C according to the product guidance.

Scope and Limitations

This is a dossier-grounded research-use guide, not a literature review or clinical recommendation. The reported IC50, solubility values, purity specification, selectivity comparisons, and storage condition come from the product information. No directly matched paper evidence is available here to establish a preferred cell line, exposure schedule, validated phenotypic concentration, or comparative efficacy result.

The dossier describes oral activity in animal tumor models and states that BFH772 has advanced into clinical studies for rosacea. These statements provide development context only; they do not establish an outcome for a new animal, cellular, or clinical experiment. Do not extrapolate oral exposure or tumor-model effects to an in vitro protocol without pharmacokinetic and assay-specific validation.

BFH772 is therefore best treated as a selective VEGFR2 kinase inhibitor for angiogenesis research, not as a broad-spectrum kinase inhibitor or a water-soluble reagent. Purity above 96% also does not establish sterility, endotoxin status, or suitability for a particular biological administration route. Confirm all additional requirements independently.

Conclusion

BFH772 provides a practical way to test VEGFR2-linked signaling and angiogenic phenotypes when controlled organic-solvent delivery is acceptable. Start with the dossier-reported 3 nM biochemical potency as a planning reference, not a predetermined biological dose; control solvent and precipitation carefully; and pair angiogenic readouts with target-level and viability controls. These safeguards keep conclusions proportional to the available evidence and the actual assay conditions.